Which Has Less Side Effects: Losartan or Olmesartan?

Overall side-effect rates for losartan and olmesartan are close enough that most head-to-head trials describe both drugs as “well tolerated,” with headache, dizziness, and mild fatigue topping the list for each. A recent network meta-analysis actually found olmesartan associated with fewer adverse events than losartan across hypertension trials. Yet the two drugs differ in a few clinically meaningful ways that rarely show up in simple side-effect percentages, including a rare but serious gut problem linked mainly to olmesartan, a unique benefit losartan has on uric acid, and real differences in how each drug interacts with other medications.

What Head-to-Head Trials Show About Overall Tolerability

When researchers compare losartan and olmesartan directly, the side-effect profiles look remarkably similar. In a randomized trial of patients with stage 1 or stage 2 hypertension receiving maximum doses of each drug, both were well tolerated, and headache was the most common complaint in both groups.¹ A separate multi-drug comparison of olmesartan, losartan, valsartan, and irbesartan concluded simply that all drugs were well tolerated.² In a three-way comparison among olmesartan, telmisartan, and losartan, treatment-related adverse events occurred in about 5% of the olmesartan group, with no serious events reported in any arm.³

At the broadest level, a network meta-analysis pooling data across six different ARBs found that olmesartan and telmisartan were actually associated with fewer adverse events than losartan.⁴ That may seem counterintuitive given some of the concerns covered below, but it reflects how the drugs stack up across thousands of patients in standard clinical use. The common side effects for both, things like dizziness, headache, and occasional cough, occur at low frequencies and tend to be mild.⁵

Olmesartan’s Specific Gut Problem

The single biggest differentiator between these two drugs is a rare intestinal condition called sprue-like enteropathy. It mimics celiac disease, causing chronic diarrhea, weight loss, and damage to the lining of the small intestine. Although other ARBs have been linked to isolated cases, olmesartan dominates the reports by a wide margin.

A systematic review of published case reports found 233 cases tied to olmesartan, representing 94% of all ARB-associated sprue-like enteropathy cases. Losartan accounted for just 2 cases, or 0.8%. In the reported cases, gut biopsies showed damage to the intestinal villi in over 90% of patients, along with an abnormal accumulation of immune cells in the gut lining in about 60%.⁶ A separate tally of 73 confirmed case reports with documented recovery found 59 attributable to olmesartan and only 2 to losartan.⁷

The onset is unpredictable. In published reports, symptoms appeared anywhere from two weeks to thirteen years after starting the drug.⁶ That long delay makes it easy for patients and even doctors to miss the connection, which is partly why the condition went unrecognized until a Mayo Clinic case series brought attention to it. Once the drug is stopped, the gut lining typically heals within three to twelve months.⁷

A large multi-database study put some population-level numbers on this. After adjusting for other risk factors, olmesartan users had a roughly 21% higher rate of celiac disease diagnoses and a 22% higher rate of simultaneous diarrhea and weight loss compared with users of other ARBs. For the broader category of non-infectious enteropathy, the difference was smaller but still present.⁸ It is worth noting that some researchers have pointed out the cohort studies do not show as dramatic a difference as the case reports suggest, and whether other ARBs genuinely carry a lower risk or are simply underreported remains an open question.⁷ Still, if you develop unexplained chronic diarrhea or significant weight loss while taking olmesartan, the drug should be on the list of possible culprits.

Losartan’s Uric Acid Advantage

Losartan has a quirk that no other ARB shares to the same degree: it lowers uric acid levels in the blood. This matters if you have gout or are at risk for it, because high uric acid is what drives gout attacks. Losartan achieves this by interacting with a kidney transporter called MRP4 that helps move uric acid out of the body. Lab data show that losartan blocks this transporter at concentrations that match what actually occurs in kidney tissue during normal dosing.⁹

Olmesartan, by contrast, interacts with a different transporter (OAT3) and does not produce the same uric-acid-lowering effect in practice. This is not exactly a “side effect” comparison, but it is a real clinical difference. For someone who needs blood pressure medication and also has elevated uric acid or a history of gout, losartan offers a two-for-one benefit that olmesartan simply does not. Some clinicians choose losartan specifically for this reason, even when another ARB might lower blood pressure a bit more aggressively.

Drug Interactions and How Each Is Metabolized

This is where olmesartan has a clear practical advantage. Losartan is broken down in the liver primarily through two enzyme pathways, CYP2C9 and CYP3A4. These same pathways process a long list of other common medications, including certain antifungals, some antibiotics, and several heart drugs. When losartan is taken alongside another drug that competes for these enzymes, blood levels of one or both drugs can change in unpredictable ways.¹⁰

Olmesartan bypasses this system entirely. Its metabolism does not depend on the liver enzymes that handle most other drugs, which means no dose adjustments are generally needed when combining it with other medications.¹⁰ If you take several prescription medications, this can be a meaningful advantage. One less thing for your doctor or pharmacist to worry about in terms of drug combinations going sideways.

Losartan also has an active metabolite called EXP3174 that is actually responsible for much of its blood-pressure-lowering effect. Because the conversion depends on CYP2C9, people who are slow metabolizers of that enzyme, a genetic trait that is more common in some populations, may get less benefit from losartan. Olmesartan does not have this wrinkle; its parent compound is the active drug.

Concerns in Diabetic Kidney Disease

One study raised a specific safety flag for olmesartan in patients with type 2 diabetes and advanced kidney disease. In the ORIENT trial, which tested olmesartan against placebo on top of standard therapy, the olmesartan group had a higher number of cardiovascular deaths compared with placebo (ten versus three), though the overall rates of major cardiovascular events and all-cause death were similar between the groups. The olmesartan group also experienced more episodes of high potassium, with about 9% developing hyperkalemia compared to roughly 5% in the placebo group.¹¹

This trial studied a very specific, high-risk population, not the average person with hypertension. Still, the cardiovascular death signal was enough to generate debate in nephrology circles. Losartan, by contrast, has decades of data in diabetic kidney disease, most famously from the RENAAL trial, and is one of the more commonly chosen ARBs for this population. If you have diabetes with significant kidney involvement, this is a conversation worth having with your doctor, because the choice between these two drugs may matter more in your case than it does for someone with straightforward high blood pressure.

Potassium and Electrolyte Effects

All ARBs can raise potassium levels to some degree, because they reduce aldosterone, the hormone that tells your kidneys to excrete potassium. In otherwise healthy people with normal kidneys, this rarely causes problems. But in people with reduced kidney function, diabetes, or those already taking potassium-sparing diuretics, the risk of potassium climbing too high goes up.

The ORIENT trial data mentioned above showed a higher hyperkalemia rate with olmesartan in advanced diabetic kidney disease.¹¹ Whether olmesartan is inherently worse than losartan for potassium in the general population is harder to say, because the difference only showed up clearly in a high-risk group. Routine lab monitoring of potassium is standard practice with any ARB, and there is no strong evidence that one drug requires more vigilant monitoring than the other in people with healthy kidneys.

Blood Pressure Lowering and Why It Matters for Side Effects

Olmesartan tends to lower blood pressure a bit more than losartan at their respective standard doses. The head-to-head trial of maximum doses found olmesartan achieved superior blood pressure reductions with similar tolerability.¹ This is relevant to side effects because the most common complaints with any ARB, things like dizziness and lightheadedness, are often dose-related and tied to how much the blood pressure drops. A drug that is more potent per milligram can be titrated to a lower dose to reach the same blood pressure target, which can help manage those symptoms.

On the flip side, if someone starts olmesartan and their blood pressure dips too low, dizziness and fatigue can be more pronounced than they would be on a milder dose of losartan. This is more of a dosing consideration than a fundamental drug safety difference, but it is something prescribers account for, especially in older adults or people who are prone to low blood pressure.

Quality of Life on Either Drug

You might expect that small differences in side effects would show up in quality-of-life surveys, but the data suggest otherwise. A study that measured health-related quality of life in patients taking various ARBs, including losartan and olmesartan, found no meaningful differences in quality-of-life scores between the drugs. Blood pressure came down, but daily well-being was essentially the same regardless of which ARB was used. For most people, day-to-day life on losartan and day-to-day life on olmesartan feel indistinguishable.

When the Choice Might Actually Matter

For the majority of people with high blood pressure and no other complicating conditions, the practical difference in side effects between losartan and olmesartan is small enough that other considerations, like insurance formulary, cost, and once-daily convenience, tend to drive the choice. But a few scenarios tilt the scales:

History of gout or high uric acid: Losartan’s uric-acid-lowering effect gives it a concrete advantage that olmesartan lacks.
Multiple other medications: Olmesartan’s lack of liver enzyme interactions makes it a simpler choice in complex drug regimens.
Unexplained chronic diarrhea on an ARB: If you are taking olmesartan and develop persistent diarrhea or unexplained weight loss, the enteropathy risk is real and should prompt a conversation about switching.
Advanced diabetic kidney disease: The cardiovascular signal from the ORIENT trial makes some clinicians prefer losartan or other ARBs with more reassuring long-term data in this population.

Neither drug is categorically “safer” than the other. The network meta-analysis data suggesting olmesartan has fewer overall adverse events than losartan is legitimate, but it captures the everyday experience and does not fully account for rare events like enteropathy that may take years to appear. If anything, the evidence suggests the two drugs are more alike than different for the average patient, and the specific differences that do exist are the kind that only matter when they apply to your particular medical picture.

Switching Between the Two

If you are already on one of these drugs and tolerating it well, there is generally no compelling reason to switch purely for side-effect purposes. Switching ARBs is straightforward, since they work through the same receptor, but dose equivalence is not one-to-one. Olmesartan at 20 mg is often compared to losartan at 50-100 mg for blood pressure lowering. A direct swap without dose adjustment can lead to a period of under-treatment or over-treatment of blood pressure, with accompanying symptoms.

For people who develop a suspected side effect on one drug, switching to the other is a reasonable first step before abandoning the ARB class altogether. The sprue-like enteropathy linked to olmesartan, for example, typically resolves after discontinuation, and there is no evidence that switching to losartan carries a meaningful risk of the same gut problem. Conversely, someone experiencing drug interactions on losartan due to other medications may find olmesartan smoother to manage alongside their existing regimen.¹⁰

One thing to be aware of when switching: because losartan depends on liver enzyme conversion to produce its active metabolite, the blood-pressure-lowering effect can take a day or two to reach full strength after starting. Olmesartan, already in its active form, tends to kick in faster. This is a minor practical point, but worth knowing if your doctor asks you to monitor your blood pressure at home during the transition.